New pill aims to tame stubborn high blood pressure

NCT ID NCT07686120

Not yet recruiting Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This study tests whether a new drug called baxdrostat can lower blood pressure in Chinese adults whose hypertension remains uncontrolled despite taking two or more blood pressure medications. Participants receive either baxdrostat or a placebo daily for 12 weeks, while continuing their usual medications. The main goal is to see if baxdrostat reduces average systolic blood pressure over 24 hours compared to placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: baxdrostat
What this could lead to: If successful, baxdrostat could offer a new oral option to help lower blood pressure in people whose hypertension is not controlled by multiple existing medications.
What could go wrong: This is a Phase 3 trial, but results may not apply to all populations. The drug may cause side effects like low blood pressure or electrolyte imbalances, and it may not prove more effective than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UNCONTROLLED HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UNCONTROLLED HYPERTENSION

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.